Spots Global Cancer Trial Database for Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Official Title: A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors
Study ID: NCT00603356
Conditions
Interventions
Study Description
Brief Summary: This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
Detailed Description: Multicenter, open-label, phase 1, dose escalation study to determine the maximum tolerated dose of OSI-930 and Erlotinib. Patients may continue to receive OSI-930 and Erlotinib until one of the following occurs: disease progression, adverse event requiring withdrawal, failure to recover from toxicity despite a 14-day dosing interruption, medical or ethical reasons, patient request, or patient death.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
The Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
